🚀
Enjoy a 7-Day Free Trial Thru May 02, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Savara Inc (NAS:SVRA)
News
Savara Inc
1
NAS
:SVRA (USA) Â
$ 4.17
-0.07 (-1.65%)
10:08 AM EST
P/E:
At Loss
P/B:
4.09
Market Cap:
$ 576.08M
Enterprise V:
$ 464.43M
Volume:
113.17K
Avg Vol (2M):
836.80K
Warning! GuruFocus detected 2 Severe warning signs with SVRA.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
113.17K
Market Cap $:
576.08M
PE Ratio:
At Loss
Avg Vol (2M):
836.80K
Enterprise Value $:
464.43M
PB Ratio:
4.09
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Savara Inc (NAS:SVRA) Stock News, Headlines & Updates
Savara Inc Stock News from GuruFocus
Total 84
1
2
3
Apr 08, 2024
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Business Wire
•
8:00am
Mar 22, 2024
Savara Announces New Employment Inducement Grant
Business Wire
•
4:00pm
Mar 07, 2024
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Business Wire
•
4:00pm
Mar 06, 2024
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
Business Wire
•
4:00pm
Feb 09, 2024
Savara Inc at Guggenheim Healthcare Talks Biotechnology Conference Transcript
GuruFocus Research
•
10:43pm
Savara Inc at Jefferies Healthcare Conference Transcript
GuruFocus Research
•
10:43pm
Savara Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
GuruFocus Research
•
10:43pm
Savara Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
10:43pm
Q2 2020 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Savara Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
10:43pm
Q1 2020 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Savara Inc. - Special Call Transcript
GuruFocus Research
•
10:43pm
Q4 2019 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Q3 2019 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Q2 2019 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Savara Inc Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) Transcript
GuruFocus Research
•
10:43pm
Q1 2019 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Q4 2018 Savara Inc Earnings Call Transcript
GuruFocus Research
•
10:43pm
Dec 30, 2023
Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA)
GuruFocus Research
•
8:01am
Dec 21, 2023
Savara Introduces aPAP ClearPathâ„¢, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire
•
8:00am
Dec 20, 2023
Savara Added to the NASDAQ Biotechnology Index
Business Wire
•
8:00am
Dec 15, 2023
Savara Announces New Employment Inducement Grant
Business Wire
•
4:00pm
Nov 21, 2023
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
Business Wire
•
8:00am
Nov 09, 2023
Savara Reports Third Quarter Financial Results and Provides Business Update
Business Wire
•
4:00pm
Nov 08, 2023
Savara to Present at the Jefferies London Healthcare Conference
Business Wire
•
4:00pm
Oct 06, 2023
Savara Announces New Employment Inducement Grant
Business Wire
•
4:00pm
Sep 05, 2023
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Business Wire
•
4:00pm
Aug 10, 2023
Savara Reports Second Quarter Financial Results and Provides Business Update
Business Wire
•
4:00pm
Aug 04, 2023
Savara Announces New Employment Inducement Grant
Business Wire
•
4:00pm
Jul 13, 2023
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Business Wire
•
7:00am
Jun 26, 2023
Savara Added to Russell 3000® Index
Business Wire
•
4:00pm
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire
•
8:00am
Jul 16, 2021
3 Net Current Asset Value Stock Picks
Alberto Abaterusso
•
8:12am
Jun 30, 2021
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
Business Wire
•
10:00am
May 26, 2021
Savara to Present at the Jefferies Virtual Healthcare Conference
Business Wire
•
8:01am
May 17, 2021
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
Business Wire
•
8:00am
May 14, 2021
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
•
8:00am
May 13, 2021
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
Business Wire
•
4:01pm
Mar 11, 2021
Savara Announces Pricing of Public Offering of Common Stock
Business Wire
•
11:01am
Savara Announces Proposed Public Offering of Common Stock
Business Wire
•
7:00pm
Total 84
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news